Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD-CAA prevention (KD-CAAP) trial

Eleftheriou D., Connon R., Tulloh R., Martin N., Kucera F., Christov G., Kahn R., Mossberg M., Nordenhäll C., Bailhache M., Palmu S., Webb C., McCrossan B., Herberg J., Moraes YC., McCormack R., Stone J., Hunter R., Walker AS., Brogan P., Merida Morillas M., Pursell M., Papadopoulou C., AlObaidi M., Moraitis E., Walsh J., McLellan K., Ilina M., Jansen M., Iro M., Dewals W., Laan M., Van Onzenoort L., Langer D., Coles W., Paulus S., Williams E., Núñez-Cuadros E., Antón J., Hertting O., De Somer L., Berg S., Panzer J., Meerschaut I., Jõgi P., Huet F., Jeziorski E., von Both U., Jakob A., Krickau T., Rosina S., Simonini G., Taddio A., Fernandez Cooke E., Miller O., Sefi E., Levin M., Swallow V., Wan M., Standing J., Pang K., Wyncoll J.